Find a Doctor

Daniel Aletaha

European League Against Rheumatism Standing Committees
Male

Bio


They have been an author on 242 peer reviewed articles and participated in 1 clinical trial in the past 15 years.

Contact

CH

Latest Advances


Latest Advance
Study
  • Condition: Rheumatoid Arthritis (RA)
  • Journal: Annals of the rheumatic diseases
  • Treatment Used: Disease-Modifying Antirheumatic Drugs (DMARDs)
  • Number of Patients: 274
  • Published —
This study determined if disease duration and number of prior disease-modifying antirheumatic drugs (DMARDs) affect response to therapy in patients with established rheumatoid arthritis (RA).
Latest Advance
Study
  • Condition: Rheumatoid Arthritis (RA)
  • Journal: Rheumatic diseases clinics of North America
  • Treatment Used: Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug (csDMARD)Therapy vs. Methotrexate (MTX) as the Initial Treatment of Choice
  • Number of Patients: 0
  • Published —
This article discusses whether triple conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) improve upon methotrexate (MTX) as the initial treatment of choice for patients with rheumatoid arthritis (RA).
Latest Advance
Study
  • Condition: Early Inflammatory Arthritis
  • Journal: Arthritis research & therapy
  • Treatment Used: Infliximab plus Methotrexate
  • Number of Patients: 99
  • Published —
This study explored the effects of immediate induction therapy with the anti-tumour necrosis factor (TNF)? antibody infliximab (IFX) plus methotrexate (MTX) compared with MTX alone and with placebo (PL) in patients with very early inflammatory arthritis.
Latest Advance
Study
  • Condition: Active Rheumatoid Arthritis
  • Journal: Lancet (London, England)
  • Treatment Used: Sirukumab
  • Number of Patients: 878
  • Published —
This study tested the safety and efficacy of treating active rheumatoid arthritis in patients who reacted negatively to anti-TNF therapy with sirukumab.

All Publications
View All


Publication
Conference
  • Sponsor: American College of Rheumatology (ACR)
  • Event Name: American College of Rheumatology Annual Scientific Meeting 2020
  • Published —
Impact of Upadacitinib or Adalimumab as Initial Therapy on the Achievement of 48-Week Treatment Goals in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Post Hoc Analysis of a Phase 3 Study
Publication
Conference
  • Sponsor: American College of Rheumatology (ACR)
  • Event Name: American College of Rheumatology Annual Scientific Meeting 2020
  • Published —
Associations Between Rheumatoid Arthritis Disease Activity and Patient-reported Outcomes in Sarilumab Clinical Trials

Contact

CH

Insurance

Contact them to find out if they accept your insurance plan.